Literature DB >> 30631565

The importance of PD-L1 diagnostic assay harmonization for the selection of lung cancer immunotherapy.

Juan-Manuel Hernandez-Martinez1,2, Zyanya Lucia Zatarain-Barrón1, Andrés F Cardona3,4,5, Oscar Arrieta1.   

Abstract

Entities:  

Year:  2018        PMID: 30631565      PMCID: PMC6297543          DOI: 10.21037/jtd.2018.10.24

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  22 in total

1.  First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.

Authors:  David P Carbone; Martin Reck; Luis Paz-Ares; Benjamin Creelan; Leora Horn; Martin Steins; Enriqueta Felip; Michel M van den Heuvel; Tudor-Eliade Ciuleanu; Firas Badin; Neal Ready; T Jeroen N Hiltermann; Suresh Nair; Rosalyn Juergens; Solange Peters; Elisa Minenza; John M Wrangle; Delvys Rodriguez-Abreu; Hossein Borghaei; George R Blumenschein; Liza C Villaruz; Libor Havel; Jana Krejci; Jesus Corral Jaime; Han Chang; William J Geese; Prabhu Bhagavatheeswaran; Allen C Chen; Mark A Socinski
Journal:  N Engl J Med       Date:  2017-06-22       Impact factor: 91.245

Review 2.  Companion and Complementary Diagnostics-Focus on PD-L1 Expression Assays for PD-1/PD-L1 Checkpoint Inhibitors in Non-Small Cell Lung Cancer.

Authors:  Maria Hersom; Jan T Jørgensen
Journal:  Ther Drug Monit       Date:  2018-02       Impact factor: 3.681

3.  Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.

Authors:  Scott Gettinger; Naiyer A Rizvi; Laura Q Chow; Hossein Borghaei; Julie Brahmer; Neal Ready; David E Gerber; Frances A Shepherd; Scott Antonia; Jonathan W Goldman; Rosalyn A Juergens; Scott A Laurie; Faith E Nathan; Yun Shen; Christopher T Harbison; Matthew D Hellmann
Journal:  J Clin Oncol       Date:  2016-06-27       Impact factor: 44.544

Review 4.  Nivolumab and pembrolizumab: Monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable.

Authors:  Vinay Prasad; Victoria Kaestner
Journal:  Semin Oncol       Date:  2017-07-13       Impact factor: 4.929

Review 5.  Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art?

Authors:  Keith M Kerr; Ming-Sound Tsao; Andrew G Nicholson; Yasushi Yatabe; Ignacio I Wistuba; Fred R Hirsch
Journal:  J Thorac Oncol       Date:  2015-07       Impact factor: 15.609

6.  PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project.

Authors:  Fred R Hirsch; Abigail McElhinny; Dave Stanforth; James Ranger-Moore; Malinka Jansson; Karina Kulangara; William Richardson; Penny Towne; Debra Hanks; Bharathi Vennapusa; Amita Mistry; Rasika Kalamegham; Steve Averbuch; James Novotny; Eric Rubin; Kenneth Emancipator; Ian McCaffery; J Andrew Williams; Jill Walker; John Longshore; Ming Sound Tsao; Keith M Kerr
Journal:  J Thorac Oncol       Date:  2016-11-29       Impact factor: 15.609

7.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

Authors:  Martin Reck; Delvys Rodríguez-Abreu; Andrew G Robinson; Rina Hui; Tibor Csőszi; Andrea Fülöp; Maya Gottfried; Nir Peled; Ali Tafreshi; Sinead Cuffe; Mary O'Brien; Suman Rao; Katsuyuki Hotta; Melanie A Leiby; Gregory M Lubiniecki; Yue Shentu; Reshma Rangwala; Julie R Brahmer
Journal:  N Engl J Med       Date:  2016-10-08       Impact factor: 91.245

8.  Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas.

Authors:  Andreas H Scheel; Manfred Dietel; Lukas C Heukamp; Korinna Jöhrens; Thomas Kirchner; Simone Reu; Josef Rüschoff; Hans-Ulrich Schildhaus; Peter Schirmacher; Markus Tiemann; Arne Warth; Wilko Weichert; Rieke N Fischer; Jürgen Wolf; Reinhard Buettner
Journal:  Mod Pathol       Date:  2016-07-08       Impact factor: 7.842

9.  A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer.

Authors:  David L Rimm; Gang Han; Janis M Taube; Eunhee S Yi; Julia A Bridge; Douglas B Flieder; Robert Homer; William W West; Hong Wu; Anja C Roden; Junya Fujimoto; Hui Yu; Robert Anders; Ashley Kowalewski; Christopher Rivard; Jamaal Rehman; Cory Batenchuk; Virginia Burns; Fred R Hirsch; Ignacio I Wistuba
Journal:  JAMA Oncol       Date:  2017-08-01       Impact factor: 31.777

10.  Current Status of Companion and Complementary Diagnostics: Strategic Considerations for Development and Launch.

Authors:  H Scheerens; A Malong; K Bassett; Z Boyd; V Gupta; J Harris; C Mesick; S Simnett; H Stevens; H Gilbert; P Risser; R Kalamegham; J Jordan; J Engel; S Chen; L Essioux; J A Williams
Journal:  Clin Transl Sci       Date:  2017-02-27       Impact factor: 4.689

View more
  2 in total

1.  Erratum to the importance of PD-L1 diagnostic assay harmonization for the selection of lung cancer immunotherapy.

Authors: 
Journal:  J Thorac Dis       Date:  2019-03       Impact factor: 2.895

2.  Clinical Significance of Tumor and Immune Cell PD-L1 Expression in Gastric Adenocarcinoma.

Authors:  Dong Hyun Kim; Go Eun Bae; Kwang Sun Suh; David Ryuman; Kyu Sang Song; Ju Seok Kim; Sang-Il Lee; Min-Kyung Yeo
Journal:  In Vivo       Date:  2020 Nov-Dec       Impact factor: 2.155

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.